Insider Stock Trading History of Lieber Jonathan I


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Lieber Jonathan I since year 2005. The trader's CIK number is 1350090. At the time of this reporting, Lieber Jonathan I is the Chief Financial Officer of Histogenics Corp . (stock ticker symbol HSGX). See this page for all insider trading activities at Histogenics Corp .

Note that in the past Lieber Jonathan I also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Lieber Jonathan I since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2016-12-02 HSGX Histogenics Corp Buy 5,000 1.95 9,730
2007-12-17 ALTU Altus Pharmaceuticals Inc. Option Ex 1,800 3.92 7,056
2007-12-17 ALTU Altus Pharmaceuticals Inc. Sale 1,800 10.03 18,054
2007-11-15 ALTU Altus Pharmaceuticals Inc. Option Ex 1,800 3.92 7,056
2007-11-15 ALTU Altus Pharmaceuticals Inc. Sale 1,800 11.35 20,430
2007-10-15 ALTU Altus Pharmaceuticals Inc. Option Ex 1,800 3.92 7,056
2007-10-15 ALTU Altus Pharmaceuticals Inc. Sale 1,800 11.46 20,628
2007-09-17 ALTU Altus Pharmaceuticals Inc. Option Ex 1,800 3.92 7,056
2007-09-17 ALTU Altus Pharmaceuticals Inc. Sale 1,800 10.27 18,486
2007-08-15 ALTU Altus Pharmaceuticals Inc. Option Ex 9,000 3.92 35,280
2007-08-15 ALTU Altus Pharmaceuticals Inc. Sale 9,000 10.42 93,780
2007-03-15 ALTU Altus Pharmaceuticals Inc. Option Ex 1,800 3.92 7,056
2007-03-15 ALTU Altus Pharmaceuticals Inc. Sale 1,800 14.23 25,614
2007-01-16 ALTU Altus Pharmaceuticals Inc. Option Ex 2,000 3.92 7,840
2007-01-16 ALTU Altus Pharmaceuticals Inc. Sale 2,000 19.24 38,480
2006-11-15 ALTU Altus Pharmaceuticals Inc. Option Ex 2,000 3.92 7,840
2006-11-15 ALTU Altus Pharmaceuticals Inc. Sale 2,000 18.61 37,220

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lieber Jonathan I (Chief Financial Officer of Histogenics Corp at the time of this reporting) see the Securities and Exchange Commission (SEC) website.